Study #2025-0520
Olutasidenib combined with co-targeted therapy in relapsed or refractory IDH1-mutated myeloid malignancies harboring activated signaling pathway mutations
MD Anderson Study Status
Enrolling
Treatment Agent
Olutasidenib, Cladribine (CLAD), Cytarabine, Venetoclax, Gilteritinib, Ruxolitinib
Description
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Targeted Therapy, IDH1-Mutated Malignancies, Mutations
Study phase:
Phase II
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.